source
- GSK licenses Chimagen trispecific T-cell engager for up to $750 million, targeting phase-1 multiple myeloma studyGSK has entered a licensing agreement with China’s Chimagen Biosciences that could be worth as much as $750 million. The deal will allow GSK to begin phase‑1 testing of a trispecific T‑cell engager…
- Blood centers poised to boost cell and gene therapy supply chainsBlood centers have the donors, resources and community footprint that drug sponsors need to address supply chain bottlenecks for cell and gene therapies. Cell and gene therapies such as CAR‑T and…